Olga Lomovskaya

List of Publications by Year
in descending order

26	3,247	331670 21	552781 26
papers	citations	h-index	g-index

26	26	26	2808
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa : Novel Agents for Combination Therapy. Antimicrobial Agents and Chemotherapy, 2001, 45, 105-116.	3.2	804
2	Discovery of a Cyclic Boronic Acid Î²-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. Journal of Medicinal Chemistry, 2015, 58, 3682-3692.	6.4	331
3	Effect and Safety of Meropenemâ€“Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infectious Diseases and Therapy, 2018, 7, 439-455.	4.0	313
4	Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	255
5	Inhibitors of Efflux Pumps in Pseudomonas aeruginosa Potentiate the Activity of the Fluoroquinolone Antibacterial Levofloxacin. Journal of Medicinal Chemistry, 1999, 42, 4928-4931.	6.4	245
6	Use of a Genetic Approach To Evaluate the Consequences of Inhibition of Efflux Pumps in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 1999, 43, 1340-1346.	3.2	195
7	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-Î²-lactamases. Journal of Medicinal Chemistry, 2020, 63, 7491-7507.	6.4	135
8	Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	126
9	Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	121
10	In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	102
11	Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2755-2758.	2.2	91
12	Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 663-667.	2.2	77
13	Peptidomimetics of Efflux Pump Inhibitors Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 763-766.	2.2	77
14	Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	72
15	Biochemical Activity of Vaborbactam. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	48
16	Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in Enterobacteriaceae , Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	36
17	Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	32
18	Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	31

#	Article	IF	Citations
19	Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	28
20	Predictive Rules of Efflux Inhibition and Avoidance in Pseudomonas aeruginosa. MBio, 2021, 12, .	4.1	28
21	In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	25
22	QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Frontiers in Microbiology, 2021, 12, 697180.	3.5	25
23	In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	16
24	In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
25	The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0216821.	3.2	11
26	Structural Basis and Binding Kinetics of Vaborbactam in Class A Î²-Lactamase Inhibition. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	9